Highlights
- The FreeStyle Libre Pro iQ continuous glucose monitoring (CGM) system can discriminate between presymptomatic stages (stage 1 and 2) of type 1 diabetes and control participants without islet autoantibodies.
- Specific CGM parameters, such as time above 140 mg/dL (TA140) and glucose variability metrics, correlate with progression risk to stage 3 clinical type 1 diabetes, identifying rapid progressors within one year.
- Comparisons reveal differing glucose profiles between FreeStyle Libre Pro iQ and Dexcom G6 systems, necessitating system-specific interpretation to ensure consistent risk stratification across platforms.
- Utilizing the 97.5th percentile threshold from control values harmonizes CGM abnormality definitions, enhancing sensitivity (75%-100%) in predicting progression to clinical diabetes.
Background
Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by progressive destruction of pancreatic beta cells, leading to insulin deficiency and hyperglycemia. Detecting T1D in its presymptomatic stages (marked by the presence of islet autoantibodies but no clinical symptoms) is crucial for timely intervention to prevent or delay onset of symptomatic (stage 3) disease. Early detection has traditionally relied on autoantibody screening and oral glucose tolerance tests (OGTT), but these methods present logistic challenges and limited sensitivity to glycemic fluctuations.
Continuous glucose monitoring (CGM) offers a dynamic and minimally invasive approach to monitoring interstitial glucose levels, potentially enabling differentiation between disease stages and improving risk stratification. Among CGM devices, the FreeStyle Libre Pro iQ has emerged as a promising candidate for staging presymptomatic T1D, yet comparative assessment against established systems like the Dexcom G6 remains vital.
Key Content
Clinical Evidence from Early-Stage T1D Cohorts Using FreeStyle Libre Pro iQ
The study by Weiss et al. (2026) involved 139 children and adolescents, including 50 controls without islet autoantibodies and 89 participants with stage 1 or 2 presymptomatic T1D. CGM data from the FreeStyle Libre Pro iQ was evaluated over a 2-year period to assess glucose variability and dysglycemia parameters.
– Participants demonstrated significant differences in CGM metrics — standard deviation (SD), coefficient of variation (CV), time above set thresholds (TA140 and TA160 mg/dL), and time in tight glucose range — across no early-stage, stage 1, and stage 2 groups.
– High-risk individuals were identified by exceeding the 97.5th percentile threshold derived from control values, with 22% of stage 1 and 52% of stage 2 individuals showing abnormal CGM patterns (p=0.017).
– Notably, none of the stage 1 patients surpassed the TA140 threshold (>15%), contrasting with 40% of stage 2 and 75% (6 of 8) of rapid progressors who developed clinical T1D within one year.
Comparison with Dexcom G6 and Methodological Harmonization
Comparative analyses revealed marked differences in CGM readings between the FreeStyle Libre Pro iQ and Dexcom G6 systems, attributable to distinct sensor technologies, calibration algorithms, and data processing methods. Despite these differences, applying the 97.5th percentile cutoff from control data for each system enabled harmonization, improving cross-platform identification of high-risk individuals.
– Sensitivity for predicting progression to clinical diabetes within one year ranged from 75%-100% for FreeStyle Libre Pro iQ and 50%-100% for Dexcom G6 when standardized thresholds were applied.
– This finding underscores the necessity for device-specific interpretation of CGM data before clinical implementation in early T1D staging and treatment decision-making.
Mechanistic and Translational Insights
Glucose variability and early dysglycemia, measurable by CGM, reflect emerging beta cell dysfunction and compromised glucose homeostasis in stage 1 and 2 T1D. The identification of TA140 as a key marker aligns with the pathophysiological transition from normoglycemia to overt hyperglycemia as autoimmunity intensifies.
Employing CGM in presymptomatic individuals facilitates objective, continuous assessment beyond traditional snapshot tests, enabling:
- Timely identification of accelerated beta cell decline.
- Patient stratification for enrollment in prevention and early intervention trials.
- Individualized therapeutic planning to delay or prevent insulin dependence.
Expert Commentary
This emerging evidence illustrates the transformative potential of CGM technologies in the presymptomatic management of T1D, moving beyond traditional biochemical and immunological markers. However, several practical and scientific considerations remain:
– Heterogeneity in CGM device outputs necessitates rigorous harmonization protocols and calibrated thresholds to avoid misclassification.
– Variability in sensor sensitivity and lag time may affect glucose concentration measurements, particularly during rapid glucose excursions common in early T1D.
– Longitudinal studies are required to validate CGM-derived biomarkers for staging and to understand the temporal progression and predictive value of different CGM parameters.
– Integration of CGM with immunological markers and genetic risk scores could enhance predictive accuracy and individualize monitoring strategies.
Clinical guidelines for T1D risk assessment currently emphasize autoimmune antibody screening, but the inclusion of CGM-derived metrics may significantly improve early diagnosis and therapeutic stratification. The FreeStyle Libre Pro iQ, with its user-friendly design and cost-effectiveness, shows promise for widespread clinical adoption, provided system-specific interpretative frameworks are established.
Conclusion
Continuous glucose monitoring with the FreeStyle Libre Pro iQ offers a novel, noninvasive approach to differentiate presymptomatic stages of type 1 diabetes and predict progression to clinical disease. CGM parameters such as glucose variability and time above threshold values serve as effective biomarkers for risk stratification. Comparative analyses highlight the need for device-specific calibration and threshold harmonization to achieve consistent and reliable clinical interpretation.
Future directions include expanding large-scale multicenter validation studies, integrating CGM data with immunogenetic markers, and developing clinical algorithms that incorporate CGM metrics for personalized risk assessment and management in early T1D. Such advancements have the potential to shift paradigms in diabetes prevention and early intervention strategies.
References
- Weiss A, Huber E, Reinmüller F, Munzinger A, Bonifacio E, Ziegler AG. Continuous glucose monitoring using the FreeStyle Libre Pro iQ in presymptomatic type 1 diabetes. Diabetologia. 2026 Sep 7. PMID: 42704479.
- American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S19-S40. PMID: 36523096.
- Ziegler AG, Bonifacio E. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012;55(7):1937-43. PMID: 22450850.
- Huang EL, Danne T, Benitez-Aguirre PZ, et al. Continuous glucose monitoring in the prediction of progression to clinical type 1 diabetes: a systematic review. Diabet Med. 2022;39(7):e14849. PMID: 35248510.
